All AbMole products are for research use only, cannot be used for human consumption.
HCV-796 is a specific inhibitor of hepatitis C virus (HCV) replication that targets protein 5B (NS5B) polymerase with IC50 of 0.01-0.14 μM for genotype 1, with EC50 of 5 nM and 9 nM against genotype 1a and 1b replicons.HCV-796 is a nonnucleoside inhibitor which binds to a site in the palm domain of the HCV polymerase. In vitro replicon resistance studies indentifies substitutions at NS5B residues C316Y/F/S, S365T/A/L, and M414I, which are located near the inhibitor binding site and confer a loss of sensitivity to HCV-796. HCV-796 shows slow binding kinetics to NS5B. The binding affinity of HCV-796 to NS5B increased 27-fold over a 3-h incubation period with an equilibrium Kd of 71 nM. Slow binding kinetics of HCV-796 is driven by slow dissociation from NS5B with a Koff of 4.9 × 10-4/s .HCV-796 at 50 mg/kg three times daily for 5 days resulted in a 2.02 log10 decrease in HCV titer with one mouse below the level of detection, whereas levels in the control mice are relatively stable (0.26 log10 decline). Seven days after stopping treatments, control mouse HCV titers are unchanged, whereas the titers in the HCV-796 group rebounded to within 1.16 log of baseline. In the chimeric mouse model, a 2.02 log10 reduction in HCV titer is seen with monotherapy, whereas a suboptimal dose of 30 mg/kg three times per day in combination with interferon demonstrated a 2.44 log10 reduction. Clinical outcomes in combination with pegylated interferon and ribavirin have revealed additive efficacy in treatment naive patients. Abnormal liver function test results are observed in 8%of HCV-796 patients treated for over 8 weeks, resulting in suspension of further trial activity .
| Molecular Weight | 446.49 |
| Formula | C22H23FN2O5S |
| CAS Number | 691852-58-1 |
| Form | Solid |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[5] Gustine Liu-Young, et al. Hepatitis C protease and polymerase inhibitors in development
| Related Anti-infection Products |
|---|
| Torcitabine
Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection research. Torcitabine (2'-Deoxy-L-cytidine) shows greater inhibition of first strand than second strand DNA synthesis. |
| ABMA
ABMA is a broad-spectrum inhibitor of intracellular toxins and pathogens. ABMA efficiently protects cells against various toxins and pathogens including viruses, intracellular bacteria and parasite. |
| DDX3-IN-1
DDX3-IN-1 is a DEAD-box polypeptide 3 (DDX3) inhibitor with CC50 values of 50 and 36 μM for HIV and HCV, respectively. DDX3-IN-1 has antiviral activity. |
| WU-04
WU-04 is a non-covalent inhibitor of SARS-CoV-2, targeting the 3CLpro protein. |
| MM3122
MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
